Our lab is committed to investigating the root causes of diseases and developing cutting-edge therapeutic strategies that can enhance the health of our community. We are primarily focused on understanding the role of proteins in cellular processes and how their malfunction can lead to the onset of diseases such as cancer, autoimmune disorders, and neurological conditions.
We specifically study protein kinases, which are signaling proteins that regulate nearly all biological processes in the body. Through our research, we aim to uncover novel kinase-driven signaling pathways and identify the mechanisms that contribute to uncontrolled signaling, which can cause cancer and inflammatory disorders.
Our ultimate goal is to leverage our fundamental research findings to create innovative therapeutic approaches that can effectively prevent and treat diseases caused by kinase dysregulation. We are confident that our expertise and knowledge will make a significant impact on the health and well-being of our community.
As a lab, we rely on the crucial support of basic research funding to translate our findings into practical applications and accelerate the development of groundbreaking treatments.
Our lab is focused on understanding the molecular mechanisms that cause kinase deregulation, leading to cancer and other diseases. Our aim is to develop innovative therapeutic strategies to prevent and treat these diseases. We incorporate a multidisciplinary research approach, collaborating with experts from various fields to accelerate the discovery of cutting-edge therapies. By leveraging our expertise and partnering with industry, we strive to make a significant impact on the treatment and prevention of kinase-driven diseases. Our ultimate goal is to translate our findings into practical applications that improve the health and well-being of our community.
Our research is committed to improving human health through the establishment of cutting-edge drug discovery programs. We drive innovative integrated structure-based discovery programs to identify new targets and on many occasions have delivered key insights how to effectively counteract kinase-driven disease pathways.
Our collaborations with industry partners enable us to bridge the gap between academic research and commercial drug development, providing a unique opportunity to accelerate our basic research discoveries into clinical applications.
Receptor tyrosine pseudokinases have emerged as critical players in developmental processes. Deregulation of this class of proteins can lead to proliferative diseases such as cancers. By integrating cutting-edge structural biology with advanced imaging technologies, innovative chemical biology and proteomics approaches, we aim to elucidate at the molecular level the structure and function of EphB6 and EphA10 and use this information to redefine EphR targetable space. This novel approach is built on years of expertise in the field of kinase drug discovery and leverages our work demonstrating that pseudokinases are druggable targets.
Overwhelming evidence associate DoubleCortin-Like Kinases (DCLK1, DCLK2, DCLK3) with several diseases, including neurodegenerative disorders and many cancers. Over the past few years, our laboratory has led the structural and functional characterisation of these understudied kinases and provided the structural basis for DCLK1 targeting by small molecules. Additionally, we elucidated how DCLK1 activity contributes to microtubule dynamics. Drawing on our expertise in kinase signalling and drug discovery, we aim to further our studies by combining advanced biochemical, biophysical, structural biology, chemical biology approaches with cutting-edge imaging technologies to develop novel class of compounds that specifically target DCLK proteins for therapeutic purposes.
News, 19 Aug 2016: First 3D map of cell-building protein linked to cancer
Members of the PEAK family of pseudokinases (PEAK1/2/3) have emerged as critical regulators of cell migration, invasion and proliferation. Several studies have demonstrated abnormal levels of PEAK proteins in aggressive cancers. Recently, we have uncovered the unique structural elements that drive their scaffolding functions and facilitate their dynamic assembly into a protein interaction hub that regulates signalling networks. We now aim to fully characterise the signal integrating function of each member of the PEAK family and provide near-atomic resolution of the interacting interfaces that contribute to abnormal signal output in cancer.
News, 27th October 2017: 3D ‘scaffold’ map to help the search for new cancer treatments
Project in collaboration with Associate Professor Kelly Rogers (Imaging facility, WEHI), Professor Roger Daly (Biomedical Discovery Institute, Monash University).
Together with the lab of Professor John Silke and a leading global pharmaceutical company, we head an academic/industry research collaboration to discover and develop novel small molecule Targeted Protein Degraders / Proteolysis Targeting Chimaeras (PROTACs), that harness the degradative capacity of Ubiquitin E3 ligases for anti-cancer therapy.
Our team collaborates extensively with researchers from across WEHI and external institutions, including leading pharmaceutical companies. All projects are multidisciplinary and innovative.